AC Immune (ACIU) Other Non-Current Liabilities (2015 - 2016)
AC Immune (ACIU) posted quarterly Other Non-Current Liabilities of $9.4 million for Q4 2016, up 53.62% year-over-year from $6.1 million in Q1 2016, and up 8551.75% quarter-over-quarter from $108662.8 in Q3 2016.
Powered by 
Analysis
AC Immune (ACIU) Other Non-Current Liabilities (2015 - 2016) Analysis & Trends
AC Immune (ACIU) has reported Other Non-Current Liabilities for 2 consecutive years, with $9.4 million the latest figure, recorded in Q4 2016.
- In Q4 2016, Other Non-Current Liabilities rose 53.62% year-over-year to $9.4 million; the TTM figure through Dec 2016 stood at $9.4 million (up 53.62% YoY), while the FY2016 annual figure was $9.5 million, up 51.62% from the prior year.
- Other Non-Current Liabilities rose to $9.4 million in Q4 2016 per ACIU's latest filing, from $108662.8 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $9.4 million in Q4 2016 and bottomed at $108662.8 in Q3 2016.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | AC Immune | 285.13 Mn | 285.13 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2016 | 9.40 Mn |
| Sep 30, 2016 | 108,662.78 |
| Dec 31, 2015 | 6.12 Mn |